Table 1 Baseline characteristics of the study subjects
|  | OHA patients (n = 2956) | non-hypoglycemia (N = 2910) | hypoglycemia (N = 46) | P-value |
|---|---|---|---|---|
Sex (male%) | 1772 (59.9%) | 1749 (60.1%) | 23 (50.0%) | 0.1653 |
Age | 65.1 ± 11.3 | 65.1 ± 11.3 | 65.9 ± 8.6 | 0.5311 |
BMIa | 25.0 ± 4.3 | 25.1 ± 4.3 | 23.5 ± 3.9 | 0.0228 |
Smoking status | 0.6357 | |||
 Current users | 614 (23.5%) | 603 (23.5%) | 11 (26.8%) |  |
 Past users | 531 (20.3%) | 525 (20.5%) | 6 (14.6%) |  |
 Never users | 1463 (56.1%) | 1439 (56.1%) | 24 (58.5%) |  |
 Diabetic duration | 10.2 ± 7.5 | 10.2 ± 7.5 | 12.4 ± 7.2 | 0.0784 |
Comorbidity | ||||
 Coronary artery diseases | 9 (0.3%) | 9 (0.3%) | 0 (0.0%) | 0.7081 |
 Cerebrovascular diseases | 276 (9.4%) | 273 (9.4%) | 3 (6.7%) | 0.5295 |
Diabetic microvascular complications | ||||
 Retinopathy | 418 (14.2%) | 413 (14.3%) | 5 (11.1%) | 0.5493 |
 Neuropathy | 345 (11.7%) | 339 (11.7%) | 6 (13.3%) | 0.7350 |
 Nephropathy | 514 (17.4%) | 508 (17.5%) | 6 (13.3%) | 0.4619 |
Medication | ||||
 Number of combined OHA | 1.3 ± 1.0 | 1.3 ± 1.0 | 2.1 ± 1.0 | <.0001 |
Clinical data | ||||
 HbA1c (NGSP) (%) | 7.8 ± 1.2 | 7.8 ± 1.2 | 7.9 ± 1.2 | 0.4905 |
 eGFRb | 76.6 ± 22.9 | 76.7 ± 22.9 | 72.7 ± 22.6 | 0.2649 |
 HDL-C | 55.6 ± 15.0 | 55.5 ± 15.0 | 56.2 ± 14.9 | 0.8018 |
 TC | 193.8 ± 37.1 | 193.9 ± 37.2 | 190.4 ± 27.6 | 0.5306 |
 TG | 155.0 ± 127.2 | 155.2 ± 127.8 | 140.8 ± 87.5 | 0.3002 |
 Uric acid | 5.2 ± 1.6 | 5.2 ± 1.6 | 4.6 ± 1.4 | 0.0325 |